Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection.

Autor:	Taguchi H; Department of Gastroenterology, Saiseikai Sendai Hospital, Kagoshima, Japan.; Department of Gastroenterology, Izumi General Medical Center, Kagoshima, Japan., Otsuka T; Department of Medical Oncology, Saga Medical Center Koseikan, Saga, Japan; otsuka-t@umin.ac.jp.; Department of Internal Medicine, Minato Medical Clinic, Fukuoka, Japan., Shimokawa M; Clinical Research Institute, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.; Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan., Arima S; Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan., Hashimoto S; Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan., Ido A; Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan., Koga F; Department of Hepatobiliary and Pancreatology, Saga Medical Center Koseikan, Saga, Japan., Ueda Y; Department of Hematology and Oncology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan., Nakazawa J; Department of Medical Oncology, Kagoshima City Hospital, Kagoshima, Japan., Komori A; Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan., Otsu S; Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan., Fukahori M; Department of Internal Medicine, Division of Gastroenterology, Kurume University Hospital, Fukuoka, Japan., Makiyama A; Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan.; Cancer Center, Gifu University Hospital, Gifu, Japan., Honda T; Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan., Shibuki T; Department of Internal Medicine, Imari Arita Kyoritsu Hospital, Saga, Japan.; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan., Mizuta T; Department of Internal Medicine, Imari Arita Kyoritsu Hospital, Saga, Japan.; Department of Internal Medicine, Fujikawa Hospital, Saga, Japan., Mitsugi K; Department of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan., Nio K; Department of Medical Oncology, Sasebo Kyosai Hospital, Nagasaki, Japan., Ide Y; Department of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan., Ureshino N; Department of Medical Oncology, Saga Medical Center Koseikan, Saga, Japan.; Department of Medical Oncology, Kimitsu Chuo Hospital, Chiba, Japan., Shirakawa T; Department of Medical Oncology, Fukuoka Wajiro Hospital, Fukuoka, Japan.; Karatsu Higashi-Matsuura Medical Association Center, Saga, Japan.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2021 Jul; Vol. 41 (7), pp. 3573-3582.
DOI:	10.21873/anticanres.15145
Abstrakt:	Background/aim: The aim of the study was to evaluate gemcitabine plus nanoparticle albumin-bound paclitaxel (GnP) and FOLFIRINOX for recurrent pancreatic cancer (rPC) after resection. Patients and Methods: Forty-four patients with rPC and 211 with de novo metastatic pancreatic cancer (mPC) who received GnP or FOLFIRINOX as first-line chemotherapy were retrospectively analyzed. Results: On crude analysis, the median overall survival (OS) was significantly longer in the rPC group than in the mPC group (14.0 vs. 10.6 months, respectively; p=0.02). However, the difference was not significant on adjusted analysis using the Cox proportional hazards model (adjusted p=0.90). Patients receiving FOLFIRINOX (n=10) and GnP (n=34) in the rPC group had comparable OS (medians, 12.2 vs. 14.4 months, respectively; p=0.82) even after adjusting for covariates using the Cox model (adjusted p=0.18). Conclusion: The outcomes of patients in the rPC and mPC groups were comparable following chemotherapy. Both FOLFIRINOX and GnP may be reasonable options for treating rPC. (Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu